Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis.

Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF 3rd, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B; Accelerating Medicines Partnership in SLE network.

Nat Immunol. 2019 Oct;20(10):1404. doi: 10.1038/s41590-019-0473-3.

PMID:
31409923
2.

The immune cell landscape in kidneys of patients with lupus nephritis.

Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF 3rd, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B; Accelerating Medicines Partnership in SLE network.

Nat Immunol. 2019 Jul;20(7):902-914. doi: 10.1038/s41590-019-0398-x. Epub 2019 Jun 17. Erratum in: Nat Immunol. 2019 Aug 13;:.

PMID:
31209404
3.

Mitigating risk of glucocorticoid toxicity during the maintenance phase of ANCA vasculitis treatment.

Singh HK, Pendergraft WF.

Clin Nephrol. 2019 Apr;91(4):206-210. doi: 10.5414/CN109557. No abstract available.

PMID:
30821685
4.

Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study.

Chanouzas D, McGregor JAG, Nightingale P, Salama AD, Szpirt WM, Basu N, Morgan MD, Poulton CJ, Draibe JB, Krarup E, Dospinescu P, Dale JA, Pendergraft WF, Lee K, Egfjord M, Hogan SL, Harper L.

BMC Nephrol. 2019 Feb 18;20(1):58. doi: 10.1186/s12882-019-1226-0.

5.

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression.

Mahoney KM, Shukla SA, Patsoukis N, Chaudhri A, Browne EP, Arazi A, Eisenhaure TM, Pendergraft WF 3rd, Hua P, Pham HC, Bu X, Zhu B, Hacohen N, Fritsch EF, Boussiotis VA, Wu CJ, Freeman GJ.

Cancer Immunol Immunother. 2019 Mar;68(3):421-432. doi: 10.1007/s00262-018-2282-1. Epub 2018 Dec 18.

6.

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.

Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV, Huizinga RB; AURA-LV Study Group.

Kidney Int. 2019 Jan;95(1):219-231. doi: 10.1016/j.kint.2018.08.025. Epub 2018 Nov 9.

PMID:
30420324
7.

Inhibitory Anti-Peroxidasin Antibodies in Pulmonary-Renal Syndromes.

McCall AS, Bhave G, Pedchenko V, Hess J, Free M, Little DJ, Baker TP, Pendergraft WF 3rd, Falk RJ, Olson SW, Hudson BG.

J Am Soc Nephrol. 2018 Nov;29(11):2619-2625. doi: 10.1681/ASN.2018050519. Epub 2018 Oct 2.

PMID:
30279272
8.

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.

Cortazar FB, Muhsin SA, Pendergraft WF 3rd, Wallace ZS, Dunbar C, Laliberte K, Niles JL.

Kidney Int Rep. 2017 Nov 14;3(2):394-402. doi: 10.1016/j.ekir.2017.11.004. eCollection 2018 Mar.

9.

Pregnancy Outcomes in Patients with Glomerular Disease Attending a Single Academic Center in North Carolina.

O'Shaughnessy MM, Jobson MA, Sims K, Liberty AL, Nachman PH, Pendergraft WF.

Am J Nephrol. 2017;45(5):442-451. doi: 10.1159/000471894. Epub 2017 Apr 27.

PMID:
28445873
10.

The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy.

Brown LC, Jobson MA, Payan Schober F, Chang EH, Falk RJ, Nachman PH, Pendergraft WF.

Am J Nephrol. 2017;45(4):365-372. doi: 10.1159/000464475. Epub 2017 Mar 18.

11.

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.

Cortazar FB, Leaf DE, Owens CT, Laliberte K, Pendergraft WF 3rd, Niles JL.

BMC Nephrol. 2017 Feb 1;18(1):44. doi: 10.1186/s12882-017-0459-z.

12.

Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Cortazar FB, Pendergraft WF 3rd, Wenger J, Owens CT, Laliberte K, Niles JL.

Arthritis Rheumatol. 2017 May;69(5):1045-1053. doi: 10.1002/art.40032. Epub 2017 Mar 31.

13.

Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis.

Jones BE, Yang J, Muthigi A, Hogan SL, Hu Y, Starmer J, Henderson CD, Poulton CJ, Brant EJ, Pendergraft WF 3rd, Jennette JC, Falk RJ, Ciavatta DJ.

J Am Soc Nephrol. 2017 Apr;28(4):1175-1187. doi: 10.1681/ASN.2016050548. Epub 2016 Nov 7.

14.

Histone modification signature at myeloperoxidase and proteinase 3 in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

Yang J, Ge H, Poulton CJ, Hogan SL, Hu Y, Jones BE, Henderson CD, McInnis EA, Pendergraft WF 3rd, Jennette JC, Falk RJ, Ciavatta DJ.

Clin Epigenetics. 2016 Aug 12;8:85. doi: 10.1186/s13148-016-0251-0. eCollection 2016.

15.

Defining Glomerular Disease in Mechanistic Terms: Implementing an Integrative Biology Approach in Nephrology.

Mariani LH, Pendergraft WF 3rd, Kretzler M.

Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2054-2060. Epub 2016 Sep 14. Review.

16.

Clinical Features of Reported Ethylene Glycol Exposures in the United States.

Jobson MA, Hogan SL, Maxwell CS, Hu Y, Hladik GA, Falk RJ, Beuhler MC, Pendergraft WF 3rd.

PLoS One. 2015 Nov 13;10(11):e0143044. doi: 10.1371/journal.pone.0143044. eCollection 2015.

17.

Recent pathogenetic advances in ANCA-associated vasculitis.

Pendergraft WF 3rd, Nachman PH.

Presse Med. 2015 Jun;44(6 Pt 2):e223-9. doi: 10.1016/j.lpm.2015.04.007. Epub 2015 May 29. Review.

PMID:
26033562
18.

Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis.

Bunch DO, Mendoza CE, Aybar LT, Kotzen ES, Colby KR, Hu Y, Hogan SL, Poulton CJ, Schmitz JL, Falk RJ, Nachman PH, Pendergraft WF, McGregor JG.

Ann Rheum Dis. 2015 Sep;74(9):1784-6. doi: 10.1136/annrheumdis-2014-206756. Epub 2015 Apr 30. No abstract available.

19.

Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials.

Corapi KM, Dooley MA, Pendergraft WF 3rd.

Arthritis Res Ther. 2015 Apr 28;17:110. doi: 10.1186/s13075-015-0621-6. Review.

20.

Dialogue: A blissful future for lupus nephritis: harnessing repeat kidney biopsies to identify meaningful biomarkers of disease.

Schober FP, Pendergraft WF 3rd.

Lupus Sci Med. 2015 Apr 1;2(1):e000083. doi: 10.1136/lupus-2015-000083. eCollection 2015. No abstract available.

21.

The receptor TREML4 amplifies TLR7-mediated signaling during antiviral responses and autoimmunity.

Ramirez-Ortiz ZG, Prasad A, Griffith JW, Pendergraft WF 3rd, Cowley GS, Root DE, Tai M, Luster AD, El Khoury J, Hacohen N, Means TK.

Nat Immunol. 2015 May;16(5):495-504. doi: 10.1038/ni.3143. Epub 2015 Apr 6.

22.

Autoantigen complementarity and its contributions to hallmarks of autoimmune disease.

Pendergraft WF 3rd, Badhwar AK, Preston GA.

J Theor Biol. 2015 Jun 21;375:88-94. doi: 10.1016/j.jtbi.2014.12.006. Epub 2014 Dec 17.

PMID:
25526886
23.

AGS, SLE, and RNASEH2 mutations: translating insights into therapeutic advances.

Pendergraft WF 3rd, Means TK.

J Clin Invest. 2015 Jan;125(1):102-4. doi: 10.1172/JCI78533. Epub 2014 Dec 15.

24.

Understanding the role of rituximab in ANCA GN: regressing toward the mean.

Pendergraft WF 3rd, Falk RJ.

J Am Soc Nephrol. 2015 Apr;26(4):771-4. doi: 10.1681/ASN.2014100997. Epub 2014 Nov 7. No abstract available.

25.

Nephrotoxic effects of common and emerging drugs of abuse.

Pendergraft WF 3rd, Herlitz LC, Thornley-Brown D, Rosner M, Niles JL.

Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1996-2005. doi: 10.2215/CJN.00360114. Epub 2014 Jul 17. Review. Erratum in: Clin J Am Soc Nephrol. 2019 Apr 5;14(4):586.

26.

Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.

Pendergraft WF 3rd, Cortazar FB, Wenger J, Murphy AP, Rhee EP, Laliberte KA, Niles JL.

Clin J Am Soc Nephrol. 2014 Apr;9(4):736-44. doi: 10.2215/CJN.07340713. Epub 2014 Mar 13.

27.

Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis.

Pendergraft WF 3rd, Niles JL.

Curr Opin Rheumatol. 2014 Jan;26(1):42-9. doi: 10.1097/BOR.0000000000000014. Review.

PMID:
24276086
28.

The scavenger receptor SCARF1 mediates the clearance of apoptotic cells and prevents autoimmunity.

Ramirez-Ortiz ZG, Pendergraft WF 3rd, Prasad A, Byrne MH, Iram T, Blanchette CJ, Luster AD, Hacohen N, El Khoury J, Means TK.

Nat Immunol. 2013 Sep;14(9):917-26. doi: 10.1038/ni.2670. Epub 2013 Jul 28.

29.

Fetal outcomes after rituximab exposure in women with autoimmune vasculitis.

Pendergraft WF 3rd, McGrath MM, Murphy AP, Murphy P, Laliberte KA, Greene MF, Niles JL.

Ann Rheum Dis. 2013 Dec;72(12):2051-3. doi: 10.1136/annrheumdis-2013-203833. Epub 2013 Jul 17. No abstract available.

30.

Ifosfamide-induced Fanconi syndrome and desmopressin-responsive nephrogenic diabetes insipidus.

Kamran SC, Pendergraft WF, Harmon DC, Rubin MF.

Am J Med. 2013 Jul;126(7):e7-8. doi: 10.1016/j.amjmed.2013.02.005. Epub 2013 May 16. No abstract available.

PMID:
23684064
31.

Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches.

Arazi A, Pendergraft WF 3rd, Ribeiro RM, Perelson AS, Hacohen N.

Semin Immunol. 2013 Oct 31;25(3):193-200. doi: 10.1016/j.smim.2012.11.003. Epub 2013 Jan 29. Review.

32.

Meta-analysis of human papillomavirus infection concordance.

Reiter PL, Pendergraft WF 3rd, Brewer NT.

Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2916-31. doi: 10.1158/1055-9965.EPI-10-0576. Epub 2010 Sep 10.

33.

Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis.

Ciavatta DJ, Yang J, Preston GA, Badhwar AK, Xiao H, Hewins P, Nester CM, Pendergraft WF 3rd, Magnuson TR, Jennette JC, Falk RJ.

J Clin Invest. 2010 Sep;120(9):3209-19. doi: 10.1172/JCI40034. Epub 2010 Aug 16.

34.
35.

Myeloperoxidase interacts with endothelial cell-surface cytokeratin 1 and modulates bradykinin production by the plasma Kallikrein-Kinin system.

Astern JM, Pendergraft WF 3rd, Falk RJ, Jennette JC, Schmaier AH, Mahdi F, Preston GA.

Am J Pathol. 2007 Jul;171(1):349-60.

36.

New insights that link microbes with the generation of antineutrophil cytoplasmic autoantibodies: the theory of autoantigen complementarity.

Preston GA, Pendergraft WF 3rd, Falk RJ.

Curr Opin Nephrol Hypertens. 2005 May;14(3):217-22. Review.

PMID:
15821413
37.

Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease.

Pendergraft WF 3rd, Pressler BM, Jennette JC, Falk RJ, Preston GA.

J Mol Med (Berl). 2005 Jan;83(1):12-25. Epub 2004 Dec 11. Review.

PMID:
15592920
38.

Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis.

Yang JJ, Pendergraft WF, Alcorta DA, Nachman PH, Hogan SL, Thomas RP, Sullivan P, Jennette JC, Falk RJ, Preston GA.

J Am Soc Nephrol. 2004 Aug;15(8):2103-14.

39.

Proteinase 3 sidesteps caspases and cleaves p21(Waf1/Cip1/Sdi1) to induce endothelial cell apoptosis.

Pendergraft WF 3rd, Rudolph EH, Falk RJ, Jahn JE, Grimmler M, Hengst L, Jennette JC, Preston GA.

Kidney Int. 2004 Jan;65(1):75-84. Erratum in: Kidney Int. 2004 Mar;65(3):1130.

40.

Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3.

Pendergraft WF 3rd, Preston GA, Shah RR, Tropsha A, Carter CW Jr, Jennette JC, Falk RJ.

Nat Med. 2004 Jan;10(1):72-9. Epub 2003 Dec 7.

PMID:
14661018
41.

Novel effects of neutrophil-derived proteinase 3 and elastase on the vascular endothelium involve in vivo cleavage of NF-kappaB and proapoptotic changes in JNK, ERK, and p38 MAPK signaling pathways.

Preston GA, Zarella CS, Pendergraft WF 3rd, Rudolph EH, Yang JJ, Sekura SB, Jennette JC, Falk RJ.

J Am Soc Nephrol. 2002 Dec;13(12):2840-9.

42.

Internalization of proteinase 3 is concomitant with endothelial cell apoptosis and internalization of myeloperoxidase with generation of intracellular oxidants.

Yang JJ, Preston GA, Pendergraft WF, Segelmark M, Heeringa P, Hogan SL, Jennette JC, Falk RJ.

Am J Pathol. 2001 Feb;158(2):581-92.

43.

ANCA antigens, proteinase 3 and myeloperoxidase, are not expressed in endothelial cells.

Pendergraft WF, Alcorta DA, Segelmark M, Yang JJ, Tuttle R, Jennette JC, Falk RJ, Preston GA.

Kidney Int. 2000 May;57(5):1981-90.

Supplemental Content

Loading ...
Support Center